Intravenous push lacosamide: Successful implementation and patient outcomes across a health system

This is the authors' abstract. We don't add key points for this paper.

Intravenous administration of the antiseizure medication lacosamide can be delayed given operational challenges related to short beyond-use-dating and controlled substance requirements. The purpose of this study was to describe the steps required to successfully transition from intravenous piggyback administration to intravenous push administration and demonstrate that workflow changes improved time to administration without compromising patient safety.